← Leaderboards
Bruce R. Blazar
University Of Minnesota
$144,460,093
Attributed
$182,832,099
Total exposure
40
Grants
37
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $22.2M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$191,723,927 · 41
By mechanism
UL1$87,509,955 · 8
R01$45,718,972 · 14
UM1$23,126,699 · 1
P01$20,470,160 · 13
R37$8,040,736 · 2
KL2$6,802,650 · 2
Top collaborators
- Keli L Hippen8 shared
- Daniel J Weisdorf7 shared
- Hans-Peter Kiem5 shared
- Randolph J. Noelle4 shared
- Peter A Crawford3 shared
- Damien A Fair3 shared
- Milton Eder1 shared
- Sheila Riggs1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Jeffrey S Miller$32,066,338
- John E Wagner$7,593,142
- Rita C. R. Perlingeiro$15,900,680
- Martin Felices$2,733,593
- Branden S Moriarity$9,306,595
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsT-LymphocytePreventIn VivoPathway InteractionsSignal TransductionResponseGenerationsMediatingInsightImmuneBaseAffectTissuesImmune ResponseAllogenicNovel StrategiesCytokineRegulatory T-LymphocyteInjuryBone Marrow TransplantationClinical TrialsProgramsOrgan
Grant awards (200)
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$7,699,733
UM1 · FY2025 · TR · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$683,148
R01 · FY2025 · HL · contact PI
In Vivo Prevention of Murine GVHD$589,718
R37 · FY2025 · AI · contact PI
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics$585,829
P01 · FY2025 · CA · contact PI
Metabolomics of cGVHD$567,033
P01 · FY2025 · HL · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$7,699,733
UM1 · FY2024 · TR · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$671,440
R01 · FY2024 · HL · contact PI
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$656,304
R01 · FY2024 · HL · contact PI
In Vivo Prevention of Murine GVHD$589,718
R37 · FY2024 · AI · contact PI
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics$565,672
P01 · FY2024 · CA · contact PI
Metabolomics of cGVHD$553,947
P01 · FY2024 · HL · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$7,727,233
UM1 · FY2023 · TR · contact PI
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$811,794
R01 · FY2023 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$696,797
R01 · FY2023 · HL · contact PI
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$669,698
R01 · FY2023 · HL · contact PI
Project 3: Role of Novel Pathways in Regulating Allogeneic Immune Responses$643,776
P01 · FY2023 · AI · contact PI
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics$595,443
P01 · FY2023 · CA · contact PI
In Vivo Prevention of Murine GVHD$589,718
R37 · FY2023 · AI · contact PI
Metabolomics of cGVHD$569,841
P01 · FY2023 · HL · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$5,778,038
UL1 · FY2022 · TR · contact PI
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$751,370
R01 · FY2022 · HL
Enhancing Treg Therapeutic Efficacy in GVHD$722,503
R01 · FY2022 · HL · contact PI
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$662,404
R01 · FY2022 · HL · contact PI
Project 3: Role of Novel Pathways in Regulating Allogeneic Immune Responses$643,774
P01 · FY2022 · AI · contact PI
In Vivo Prevention of Murine GVHD$603,468
R37 · FY2022 · AI · contact PI
Metabolomics of cGVHD$594,184
P01 · FY2022 · HL · contact PI
T-Cell Targeting for GVHD$520,796
R01 · FY2022 · HL · contact PI
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$67,480
R01 · FY2022 · HL
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$5,778,038
UL1 · FY2021 · TR · contact PI
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$823,789
R01 · FY2021 · HL
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease$675,176
R01 · FY2021 · HL · contact PI
Project 3: Role of Novel Pathways in Regulating Allogeneic Immune Responses$643,775
P01 · FY2021 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$549,004
R01 · FY2021 · HL · contact PI
T-Cell Targeting for GVHD$533,936
R01 · FY2021 · HL · contact PI
In Vivo Prevention of Murine GVHD$486,900
R37 · FY2021 · AI · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$6,970,194
UL1 · FY2020 · TR · contact PI
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$849,490
R01 · FY2020 · HL
Project 3: Role of Novel Pathways in Regulating Allogeneic Immune Responses$644,997
P01 · FY2020 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$549,402
R01 · FY2020 · HL · contact PI
T-Cell Targeting for GVHD$534,296
R01 · FY2020 · HL · contact PI
In Vivo Prevention of Murine GVHD$486,950
R37 · FY2020 · AI · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$7,421,546
UL1 · FY2019 · TR · contact PI
Project 3: Role of Novel Pathways in Regulating Allogeneic Immune Responses$669,277
P01 · FY2019 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$549,793
R01 · FY2019 · HL · contact PI
In Vivo Prevention of Murine GVHD$486,999
R37 · FY2019 · AI · contact PI
T-Cell Targeting for GVHD$456,796
R01 · FY2019 · HL · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$398,904
UL1 · FY2019 · TR
Optimizing CAR T Cell Therapy$368,110
P01 · FY2019 · CA · contact PI
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment$318,733
P01 · FY2019 · CA · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$8,249,907
UL1 · FY2018 · TR · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$576,286
R01 · FY2018 · HL · contact PI
Role of Novel Pathways in Regulating Allogeneic Immune Responses$534,534
P01 · FY2018 · AI · contact PI
In Vivo Prevention of Murine GVHD$487,046
R37 · FY2018 · AI · contact PI
T-Cell Targeting for GVHD$381,812
R01 · FY2018 · HL · contact PI
Optimizing CAR T Cell Therapy$379,224
P01 · FY2018 · CA · contact PI
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment$324,847
P01 · FY2018 · CA · contact PI
University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI)$159,706
UL1 · FY2018 · TR · contact PI
Role of Novel Pathways in Regulating Allogeneic Immune Responses$553,720
P01 · FY2017 · AI · contact PI
In Vivo Prevention of Murine GVHD$497,610
R37 · FY2017 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$429,999
R01 · FY2017 · HL · contact PI
T-Cell Targeting for GVHD$381,812
R01 · FY2017 · HL · contact PI
Optimizing CAR T Cell Therapy$379,257
P01 · FY2017 · CA · contact PI
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment$324,847
P01 · FY2017 · CA · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$294,076
R01 · FY2017 · CA · contact PI
Role of Novel Pathways in Regulating Allogeneic Immune Responses$623,853
P01 · FY2016 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$429,999
R01 · FY2016 · HL · contact PI
In vivo Prevention of Murine GVHD$382,121
R01 · FY2016 · AI · contact PI
T-Cell Targeting for GVHD$381,812
R01 · FY2016 · HL · contact PI
Optimizing CAR T Cell Therapy$379,293
P01 · FY2016 · CA · contact PI
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment$324,847
P01 · FY2016 · CA · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$294,076
R01 · FY2016 · CA · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$8,891,828
UL1 · FY2015 · TR · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$1,360,530
KL2 · FY2015 · TR · contact PI
Role of Novel Pathways in Regulating Allogeneic Immune Responses$643,703
P01 · FY2015 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$423,548
R01 · FY2015 · HL · contact PI
T-Cell Targeting for GVHD$394,812
R01 · FY2015 · HL · contact PI
Optimizing CAR T Cell Therapy$394,517
P01 · FY2015 · CA · contact PI
In vivo Prevention of Murine GVHD$382,121
R01 · FY2015 · AI · contact PI
Project 2: Preclinical Drug Approaches to Chronic Graft-vs.-Host-Disease Prevention and Treatment$331,724
P01 · FY2015 · CA · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$294,076
R01 · FY2015 · CA · contact PI
Preclinical Drug Approaches to Chronic GVHD Prevention and Treatment$209,537
R01 · FY2015 · HL · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$8,891,828
UL1 · FY2014 · TR · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$1,360,530
KL2 · FY2014 · TR · contact PI
Mechanisms, Prevention and Treatment of Chronic GVHD$628,067
R01 · FY2014 · AI · contact PI
Role of Novel Pathways in Regulating Allogeneic Immune Responses$612,338
P01 · FY2014 · AI · contact PI
Enhancing Treg Therapeutic Efficacy in GVHD$442,999
R01 · FY2014 · HL · contact PI
In vivo Prevention of Murine GVHD$382,121
R01 · FY2014 · AI · contact PI
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant$327,883
P01 · FY2014 · CA · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$285,254
R01 · FY2014 · CA · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$114,000
UL1 · FY2014 · TR · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$8,180,482
UL1 · FY2013 · TR · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$1,360,530
KL2 · FY2013 · TR · contact PI
Role of Novel Inhibitory Pathways in Alloimmunity and Tolerance$546,568
P01 · FY2013 · AI · contact PI
In vivo Prevention of Murine GVHD$361,942
R01 · FY2013 · AI · contact PI
Mouse Models of Chronic Graft-vs-Host Disease$355,311
P01 · FY2013 · CA · contact PI
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant$352,360
P01 · FY2013 · CA · contact PI
Molecular Mechanisms of Thymic Epithelial Cell Involution in Aging$294,645
R01 · FY2013 · AG · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$294,076
R01 · FY2013 · CA · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$8,891,828
UL1 · FY2012 · TR · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$1,360,530
KL2 · FY2012 · TR · contact PI
Role of Novel Inhibitory Pathways in Alloimmunity and Tolerance$553,243
P01 · FY2012 · AI · contact PI
Mouse Models of Chronic Graft-vs-Host Disease$503,752
P01 · FY2012 · CA · contact PI
In vivo Prevention of Murine GVHD$392,198
R01 · FY2012 · AI · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$370,013
R01 · FY2012 · HL · contact PI
T Cell Targeting for GVHD$366,487
R01 · FY2012 · HL · contact PI
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant$342,698
P01 · FY2012 · CA · contact PI
Molecular Mechanisms of Thymic Epithelial Cell Involution in Aging$311,848
R01 · FY2012 · AG · contact PI
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant$9,297
P01 · FY2012 · CA · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$8,891,828
UL1 · FY2011 · RR · contact PI
UNIVERSITY OF MINNESOTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UMN CTSI)$4,771,977
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$2,556,401
UL1 · FY2011 · RR · contact PI
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)$1,360,530
KL2 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$852,104
UL1 · FY2011 · RR · contact PI
Role of Novel Inhibitory Pathways in Alloimmunity and Tolerance$516,137
P01 · FY2011 · AI · contact PI
Mouse Models of Chronic Graft-vs-Host Disease$508,490
P01 · FY2011 · CA · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$373,750
R01 · FY2011 · HL · contact PI
T Cell Targeting for GVHD$370,402
R01 · FY2011 · HL · contact PI
In Vivo Prevention of Murine GVHD$356,181
R01 · FY2011 · AI · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$355,673
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$355,673
UL1 · FY2011 · RR · contact PI
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant$342,796
P01 · FY2011 · CA · contact PI
Molecular Mechanisms of Thymic Epithelial Cell Involution in Aging$311,901
R01 · FY2011 · AG · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$289,239
R01 · FY2011 · CA · contact PI
Mouse Models of Chronic Graft-vs-Host Disease$521,820
P01 · FY2010 · CA · contact PI
Role of Novel Inhibitory Pathways in Alloimmunity and Tolerance$520,597
P01 · FY2010 · AI · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$373,750
R01 · FY2010 · HL · contact PI
T Cell Targeting for GVHD$370,608
R01 · FY2010 · HL · contact PI
In Vivo Prevention of Murine GVHD$359,872
R01 · FY2010 · AI · contact PI
Molecular Mechanisms of Thymic Epithelial Cell Involution in Aging$324,544
R01 · FY2010 · AG · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$298,185
R01 · FY2010 · CA · contact PI
T Progenitor and Thymic Epithelial Cell Replacement Post Transplant$246,453
P01 · FY2010 · CA · contact PI
Mouse Models of Chronic Graft-vs-Host Disease$531,898
P01 · FY2009 · CA · contact PI
Role of Novel Inhibitory Pathways in Alloimmunity and Tolerance$519,762
P01 · FY2009 · AI · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$373,750
R01 · FY2009 · HL · contact PI
T Cell Targeting for GVHD$370,809
R01 · FY2009 · HL · contact PI
In Vivo Prevention of Murine GVHD$363,598
R01 · FY2009 · AI · contact PI
Molecular Mechanisms of Thymic Epithelial Cell Involution in Aging$340,625
R01 · FY2009 · AG · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$298,185
R01 · FY2009 · CA · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$373,750
R01 · FY2008 · HL · contact PI
T Cell Targeting for GVHD$371,004
R01 · FY2008 · HL · contact PI
In Vivo Prevention of Murine GVHD$363,687
R01 · FY2008 · AI · contact PI
Cellular approaches to reduce BMT complications$354,382
R01 · FY2008 · HL · contact PI
Post BMT Lung Injury Pathophysiology$354,382
R01 · FY2008 · HL · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$298,185
R01 · FY2008 · CA · contact PI
T CELL TARGETING FOR GVHD$435,801
R37 · FY2007 · HL · contact PI
In Vivo Prevention of Murine GVHD$370,819
R01 · FY2007 · AI · contact PI
Post BMT Lung Injury Pathophysiology$354,382
R01 · FY2007 · HL · contact PI
Cellular approaches to reduce BMT complications$354,382
R01 · FY2007 · HL · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$352,012
R01 · FY2007 · HL · contact PI
Cytotoxic-T-Lymphocyte (CTL) Therapy of AML$298,185
R01 · FY2007 · CA · contact PI
T CELL TARGETING FOR GVHD$435,743
R37 · FY2006 · HL · contact PI
Post BMT Lung Injury Pathophysiology$364,967
R01 · FY2006 · HL · contact PI
Cellular approaches to reduce BMT complications$364,967
R01 · FY2006 · HL · contact PI
In Vivo Prevention of Murine GVHD$362,526
R01 · FY2006 · AI · contact PI
Strategies to Prevent and Repair Thymic Microenvironment$362,526
R01 · FY2006 · HL · contact PI
Nontoxic Strategies to Establish Allochimerism in Mice$362,526
R01 · FY2006 · HL · contact PI
GVL to Reduce AML Relapse After Murine Allogeneic BMT$290,383
R01 · FY2006 · CA · contact PI
T CELL TARGETING FOR GVHD$433,230
R37 · FY2005 · HL
Post BMT Lung Injury Pathophysiology$373,750
R01 · FY2005 · HL
Cellular approaches to reduce BMT complications$373,750
R01 · FY2005 · HL
In Vivo Prevention of Murine GVHD$371,250
R01 · FY2005 · AI
Strategies to Prevent and Repair Thymic Microenvironment$371,250
R01 · FY2005 · HL
Nontoxic Strategies to Establish Allochimerism in Mice$371,250
R01 · FY2005 · HL
Correction of Murine Immunodeficiencies in Utero$334,125
R01 · FY2005 · HL
GVL to Reduce AML Relapse After Murine Allogeneic BMT$297,371
R01 · FY2005 · CA
T CELL TARGETING FOR GVHD$420,615
R37 · FY2004 · HL
POST BMT LUNG INJURY PATHOPHYSIOLOGY$399,701
R01 · FY2004 · HL
Strategies to Prevent and Repair Thymic Microenvironment$371,250
R01 · FY2004 · HL
Nontoxic Strategies to Establish Allochimerism in Mice$371,250
R01 · FY2004 · HL
In Vivo Prevention of Murine GVHD$371,250
R01 · FY2004 · AI
IN UTERO TRANSFER OF HEMATOPOIETIC CELLS$361,973
R01 · FY2004 · HL
Correction of Murine Immunodeficiencies in Utero$334,125
R01 · FY2004 · HL
GVL to Reduce AML Relapse After Murine Allogeneic BMT$297,371
R01 · FY2004 · CA
T CELL TARGETING FOR GVHD$408,361
R37 · FY2003 · HL
POST BMT LUNG INJURY PATHOPHYSIOLOGY$388,207
R01 · FY2003 · HL
In Vivo Prevention of Murine GVHD$371,250
R01 · FY2003 · AI
Strategies to Prevent and Repair Thymic Microenvironment$371,250
R01 · FY2003 · HL
IN UTERO TRANSFER OF HEMATOPOIETIC CELLS$352,261
R01 · FY2003 · HL
Correction of Murine Immunodeficiencies in Utero$334,125
R01 · FY2003 · HL
GVL to Reduce AML Relapse After Murine Allogeneic BMT$297,371
R01 · FY2003 · CA
POST BMT LUNG INJURY PATHOPHYSIOLOGY$376,902
R01 · FY2002 · HL
T CELL TARGETING FOR GVHD$372,686
R37 · FY2002 · HL
In Vivo Prevention of Murine GVHD$371,250
R01 · FY2002 · AI
IN UTERO TRANSFER OF HEMATOPOIETIC CELLS$342,505
R01 · FY2002 · HL
Correction of Murine Immunodeficiencies in Utero$334,125
R01 · FY2002 · HL
NONTOXIC STRATEGIES TO ESTABLISH ALLOCHIMERISM$330,750
R01 · FY2002 · HL
GVL to Reduce AML Relapse After Murine Allogeneic BMT$297,371
R01 · FY2002 · CA
POST BMT LUNG INJURY PATHOPHYSIOLOGY$365,925
R01 · FY2001 · HL
T CELL TARGETING FOR GVHD$362,858
R37 · FY2001 · HL
IN UTERO TRANSFER OF HEMATOPOIETIC CELLS$332,529
R01 · FY2001 · HL
NONTOXIC STRATEGIES TO ESTABLISH ALLOCHIMERISM$330,750
R01 · FY2001 · HL
IN VIVO PREVENTION OF MURINE GVHD$304,156
R01 · FY2001 · AI
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMT$259,684
R01 · FY2001 · CA
CORRECTION OF MURINE IMMUNODEFICIENCIES IN UTERO$248,816
R01 · FY2001 · HL
POST BMT LUNG INJURY PATHOPHYSIOLOGY$354,069
R01 · FY2000 · HL
T CELL TARGETING FOR GVHD$353,315
R37 · FY2000 · HL
IN UTERO TRANSFER OF HEMATOPOIETIC CELLS$322,481
R01 · FY2000 · HL
IN VIVO PREVENTION OF MURINE GVHD$295,298
R01 · FY2000 · AI
NONTOXIC STRATEGIES TO ESTABLISH ALLOCHIMERISM$294,000
R01 · FY2000 · HL
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMT$253,047
R01 · FY2000 · CA